Do GLP-1 based therapies improve the immunological response to vaccination in diabetes?

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-525909-13-00

Enrollment

100

Registered

2026-07-22

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Brief summary

The fold-increase in total pneumococcal IgG antibody levels four months after vaccination.

Detailed description

The fold-increase in total IgG antibody levels one month after pneumococcal vaccination, The fold-increase in serotype specific antibody levels after pneumococcal vaccination, Effects of GLP-1 on (1) plasma inflammation markers, (2) immune cell numbers and (3) leukocyte ex vivo function, Questionnaire regarding vaccine-related solicited adverse events, Hospitalisation, ICU admission or death due to infectious disease

Interventions

DRUGPneumovax 23

DRUGoplossing voor injectie in een voorgevulde spuit Pneumokokkenpolysacharidevaccin

DRUGVictoza 6 mg/ml solution for injection in pre-filled pen

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The fold-increase in total pneumococcal IgG antibody levels four months after vaccination.	—

Secondary

Measure	Time frame
The fold-increase in total IgG antibody levels one month after pneumococcal vaccination, The fold-increase in serotype specific antibody levels after pneumococcal vaccination, Effects of GLP-1 on (1) plasma inflammation markers, (2) immune cell numbers and (3) leukocyte ex vivo function, Questionnaire regarding vaccine-related solicited adverse events, Hospitalisation, ICU admission or death due to infectious disease	—

Measure

Time frame

—

Outcome results

None listed

Source: EU CTIS · Data processed: Jul 23, 2026